As of May 31, 2022, BGI Genomics (300676.SZ) conducted approximately 446,000 and 5.7 million COVID-19 tests at the airport and Community Testing Centres respectively and is the only local COVID-19 test diagnostics provider selected for this WHO photo gallery.

With Hong Kong affected by multiple COVID-19 waves from 2020 onwards, there was a need to rapidly scale up the city's testing capabilities for high-risk communities. BGI Genomics was one of the testing organizations tasked by the Hong Kong government to conduct free coronavirus tests for high-risk groups of over 400,000 people by December 2020. Staff such as sampling team leader Irene Chik Wing-shan was among the 10 technicians who have been distributing and collecting bottles for COVID-19 tests for over 1000 care homes, which accommodate the most vulnerable group in society.

When new COVID-19 cases spiked dramatically in February 2022, BGI Genomics sent over 200 technicians to Hong Kong to conduct large-scale testing to trace and cut hidden transmission chains with citywide testing. These technicians were sent in several batches and rapidly enhanced Hong Kong's capacity for large-scale PCR testing, including gene sequencing, origin tracing, and antigen testing. They staffed our Tai Po laboratory, a temporarily inflated laboratory at the Ma On Shan Sports Center, and a laboratory at the airport.

Thus far, BGI's COVID-19 testing products have been used in over 180 countries and regions. Over 90 laboratories have been set up in more than 30 countries and regions. After supporting post-pandemic recovery, these laboratories may also help the management of other infectious diseases, provide early cancer screening and accelerate cancer precision medicine development.